Botanix Pharmaceuticals Ltd., has recently completed phase 1 of a clinical trial involving the use of synthetic cannabidiol (CBD) for the treatment of acne. The preliminary trial took place in Australia, where twenty participants applied the synthetic cannabinoid, which is called BTX 1503, topically for a month. Researchers looked towards the safety, tolerability, and phaymacokinetics (which refers to the amount of drug that remains detectable in the bloodstream after use). The trial was completed within 12 months and was deemed a huge success, with the company stating, “Top line data demonstrates that BTX 1503 has an excellent safety profile, with little to no skin irritation, and no severe adverse events were recorded.”
Previously, a study from 2014 published in the Journal of Clinical Investigation found CBD inhibited lipogenic action and the production of sebocytes in biopsies of human scalp and arm skin. Both of those processes contribute to the development of acne. Additionally, CBD produced anti-inflammatory effects.
This information has been provided by Leafly and approved by our Chief Medical Officer.